Echosens’ Post

AGA has published its first-ever living guideline for managing moderate-to-severe ulcerative colitis, streamlining treatment decisions for gastroenterologists and patients alike. Key updates include: ✅ Early use of advanced therapies over a step-up approach after 5-ASA failure. ✅ Categorization of 12 therapies into "efficacy buckets" for tailored treatment. ✅ Semiannual updates to incorporate the latest research and advancements. This new approach prioritizes personalized care for the 1.25 million Americans living with UC. 📖 Read the full guideline in Gastroenterology: https://ow.ly/sys850UahFs #UlcerativeColitis #HealthcareInnovation #IBD

Adalimumab - low efficacy for UC

Exploring the Role of Complementary and Alternative Medicines (CAMs) in GI Disorder Management As healthcare professionals, we constantly seek new ways to optimise patient care, particularly in areas where conventional treatments fall short. My recent engagement with the CPD article "Optimising the Treatment of Gastrointestinal Disorders in Primary Care" highlighted the growing need for multi-target therapies, such as CAMs, in managing functional gastrointestinal disorders (FGIDs). The biopsychosocial model discussed in the article emphasises the complex interplay between the mind and gut, where traditional pharmacotherapies often miss the mark. Having access to such evidence-based alternatives could significantly improve patient outcomes. I’m curious—where do you currently access reliable information on CAMs to make clinical decisions as a healthcare professional? How would you value having centralised access to this information in your practice? #CAMsInHealthcare #GIDisorders #FunctionalMedicine #IntegrativeHealth #AlternativeMedicine #PatientCare #HealthcareInnovation #EvidenceBasedPractice #ClinicalDecisions #HerbalMedicine #FGIDs #HealthcareProfessionals

Watch our On-Demand Broadcast, Unlocking Treatment Possibilities in PBC, to learn key aspects of primary biliary cholangitis relevant to patient management and historical treatment approaches. Experts discuss a treatment option for adult patients with PBC that will fit in clinical practice and which patients may benefit from treatment. Watch Now. bit.ly/402gJrI

🌟 Breaking Barriers in Heart Failure Management 🌟 Did you know that clinical hesitation and suboptimal prescription rates are major challenges in implementing evidence-based therapies for heart failure? 💡 In this on-demand webinar presented by Prof. Gheorghe A. Dan (Romania), you’ll learn: ✅ How to address barriers to guideline-directed medical therapy (GDMT). ✅ The impact of early patient identification and tailored treatments. ✅ Five key principles to successfully implement high-intensity heart failure therapies. 🔑 Unlock insights to improve patient outcomes, reduce hospitalizations, and lower mortality rates. 👉 Access this exclusive content now – available only to ISCP Full Members! https://lnkd.in/dP8vnr7p #HeartFailure #GDMT #ISCP #OnDemandWebinar Alberto J. Lorenzatti, MD, MTFAC, FACC Doreen Su-Yin Tan Pablo Avanzas Juan-Carlos Kaski Koji Hasegawa Dr. med. Antoni Martinez-RubioRodrigo Alonso KarleziCraig Beavers, PharmD, FACC, FAHA,FCCP,BCCP,CACPprof. dr hab. med. Krzysztof J. Filipiak Franco WT Cheng Dr Alan Fong

Watch our On-Demand Broadcast, Unlocking Treatment Possibilities in PBC, to learn key aspects of primary biliary cholangitis relevant to patient management and historical treatment approaches. Experts discuss a treatment option for adult patients with PBC that will fit in clinical practice and which patients may benefit from treatment. Watch Now. bit.ly/402gJrI

🎥 Learn key points from the panel discussion on "Supportive care for myeloma and AL amyloidosis patients" at the MPE Masterclass in May 2024. Christine Skeet, alongside other experts, provided an insightful panel discussion on multiple aspects of patient care and well-being. Watch the summary now to discover essential strategies for supporting myeloma and AL amyloidosis patients: https://lnkd.in/dfpDDR3y

I had a conversation recently with a patient about GLP-1 agonists and their potential role in managing osteoarthritis symptoms. As healthcare providers, we're constantly seeking innovative approaches to improve our patients' quality of life. Yesterday's NEJM publication reinforced what many of us have observed clinically - the strong connection between obesity and knee osteoarthritis. The groundbreaking research on semaglutide's dual benefits is particularly promising: ✅ Weight reduction ✅ Knee pain improvement This could be a additional therapy strategy for many of patients struggling with both conditions. As we continue to understand the interconnection between metabolic health and joint disease, I'm optimistic about the expanding therapeutic options available to us. Looking forward to following the developments in this space and implementing evidence-based solutions for better patient outcomes. link: https://lnkd.in/dtgnnRxy #Healthcare #MedicalResearch #Osteoarthritis #Innovation #PatientCare #Medicine #GLP1 #ClinicalPractice #NEJM

In one key study that was recently released during Kidney Week in 2024, we observed that chronic kidney disease (CKD) patients require integrated care from a network of healthcare professionals including primary care physicians (PCP) and nephrologists. Seeing a nephrologist is specifically associated with lower rates of hospitalization, ESKD transitions, and mortality. DaVita Clinical Research's work is essential to shaping how we advance kidney care, and I'm excited to see how these studies can contribute to how we serve patients. #KidneyWk: https://ow.ly/Sbeg30sIVbK

Watch our live national broadcast, Unlocking Treatment Possibilities in PBC, to learn key aspects of primary biliary cholangitis relevant to patient management and historical treatment approaches. Experts discuss a possible treatment option for adult patients with PBC that will fit in clinical practice and which patients may benefit from treatment. Watch Now. bit.ly/3X8o33U